Embedded Files
Our support services are designed to assist research teams, organizations, and companies with diverse interests and needs, providing invaluable insights into their markets' needs and discovering innovative ways to achieve their goals.
Our support services are designed to assist research teams, organizations, and companies with diverse interests and needs, providing invaluable insights into their markets' needs and discovering innovative ways to achieve their goals.
Our team of scientists has expertise in molecular diagnostics, oncology, neurology, psychedelic and pain medicine, scientific due diligence, drug discovery and testing, medical and clinical writing and review, pre-clinical studies, clinical trial protocols and Investigator Brochures (BIs), regulatory affairs (FDA, Health Canada, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA), in Australia), health economics and outcome research, Medicaid, and private payer models, tele health, AI healthtech technologies and platforms, start-up and investor advisory.
Our team of scientists has expertise in molecular diagnostics, oncology, neurology, psychedelic and pain medicine, scientific due diligence, drug discovery and testing, medical and clinical writing and review, pre-clinical studies, clinical trial protocols and Investigator Brochures (BIs), regulatory affairs (FDA, Health Canada, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA), in Australia), health economics and outcome research, Medicaid, and private payer models, tele health, AI healthtech technologies and platforms, start-up and investor advisory.
Sima Salahshor, PhD, PMP
Founder & Principal Advisor
Dr. Sima Salahshor is the founder of Shiruy Advisory, an Adjunct Professor at the University of Toronto, and a recognized expert in life sciences, healthcare, and medical policy. Her work centers on scientific strategy and clinical affairs, with research leadership spanning oncology, molecular diagnostics, medical genetics, and emerging areas such as psychedelic medicine and health technology.
Dr. Salahshor advises startups and organizations in the MedTech, AI health, and pharmaceutical sectors, guiding them through commercialization, due diligence, and business development. Additionally, she designs educational programs, evaluates diagnostic tests, and fosters collaborations that connect academia, government, and industry.
With extensive global experience, Dr. Salahshor has also served on advisory boards, boards of directors, and mentorship programs, bringing governance and leadership expertise to organizations worldwide. With an entrepreneurial mindset, she delivers strategic insight into innovation, healthcare policy, and the advancement of science.
Key Activity: Medical Genetics, Oncology and Cancer Research, Diagnostics and Prognostics, Start-up Advisory, Private Investment, Medical Imaging Technologies, Biomarkers, HealthTech, and Health AI-related Programs.
Farah Farahati, PhD
Senior Medical Economics Advisor
Dr. Farah Farahati is a Senior Medical Economics Advisor and Adjunct Professor at the University of Maryland with over 20 years of experience in health economics and outcomes research (HEOR) across U.S. and Canadian healthcare markets. She specializes in cost-effectiveness modelling, payer analytics, and ROI evaluations, supporting insurers and health systems with utilization forecasting, reimbursement optimization, and value-based care strategies.
With expertise in Medicare, Medicaid, and private payer models, Dr. Farahati advises on pricing strategies, risk adjustment, and claims-based forecasting. She has led high-impact projects for the U.S. Department of Health and Human Services, Medical Mutual, and Fresenius Medical Care, including ROI modelling for Nexobrid, which projected $450 million in national savings.
Proficient in SAS, SQL, and Stata, she has designed automated analytics pipelines and dashboards that deliver actionable insights. Through this work, Dr. Farahati helps organizations align financial performance with clinical impact, advancing sustainable and equitable healthcare value.
Key Activities: HEOR • Health Insurance • Real-World Evidence (RWE) • Medical Claims • Utilization Analytics & Forecasting • SAS • SQL • Stata
Mohammad Ebrahimzadeh, PhD
Principal Scientist
Dr. Ebrahimzadeh is a neuroscientist with over a decade of research experience in neuropharmacology and CNS drug development. He provides scientific oversight, research strategy, and medical writing expertise for Shiruy’s biotech and pharmaceutical clients. His work has contributed to peer-reviewed publications and regulatory submissions supporting innovative therapeutic programs.
Key Activities: Neuroscience and Neuropharmacology studies, CNS Drug Development, Pre-clinical Efficacy and Toxicity Studies (FDA IND-enabling), Phase 1 and 2 Clinical Trials, Regulatory Review and Submissions, Health Canada, FDA, Therapeutic Goods Administration (TGA), Data and Statistical Analysis, Project and program management.
Page updated
Google Sites
Report abuse